VJOncology Podcast

Breakthrough advances from ASCO 2025

In this ASCO 2025 edition of VJOncology podcasts, we spotlight five game-changing studies set to reshape cancer care across multiple tumor types.

Join our host and a panel of leading oncology experts as they unpack the most impactful data from this year’s American Society of Clinical Oncology Annual Meeting. Discover pivotal insights from the MATTERHORN trial in gastric cancer, explore KRAS G12C-targeted combinations in NSCLC, and delve into resistance-prevention strategies in HR+/HER2– breast cancer with findings from the SERENA-6 trial. We also explore the potential of mRNA-based bispecific antibodies for solid tumors and analyze expanded results from CheckMate 8HW in MSI-high colorectal cancer.

With commentary from top investigators including Yelena Janjigian, Alexander Spira, Michael Gnant, Timothy Yap, and Heinz-Josef Lenz, this episode offers essential updates for oncology professionals. Tune in for a concise, expert-led review of the most practice-changing research from ASCO 2025.

Expanding Cell Therapy - TILs, TCRs & CARs in Lung Cancer and Melanoma

Welcome to another episode of the VJ Oncology Podcast, where we bring you the forefront of cancer research and clinical practice. This week, we focus on the revolutionary field of cell therapy for solid tumors, with particular emphasis on lung cancer and melanoma.

Join Dr. Alison Betoff-Warner and Dr. Ben Creelan as they discuss the potential of targets like TILs, TCRs, and CAR-Ts. Learn about the challenges posed by IL-2 toxicity and discover the latest developments in emerging trials, including promising advancements in therapies targeting PREM and P53.

Don't miss out on these expert insights into the future of cancer treatment, and explore how innovative cell therapy approaches are transforming the landscape of oncology.

VJOncoAlert Journal Club

In this week’s podcast, we take you through the latest episodes of the VJOncoAlert Journal Club—a collaborative series from VJOncology and OncoAlert that brings together leading oncology experts to discuss the most impactful and practice-changing research in the field.

We are joined by Misty Shields, MD, PhD, from the Indiana University Simon Comprehensive Cancer Center in Indianapolis, IN, who discusses the latest updates in small cell lung cancer. Thomas Powles, MBBS, MRCP, MD, of Barts Cancer Institute in London, UK, and Brian Rini, MD, FASCO, of Vanderbilt-Ingram Cancer Center in Nashville, TN, comment on the health-related quality of life (HRQoL) results from the LITESPARK-005 trial (NCT04195750) in advanced renal cell carcinoma (RCC). Berend J van der Wilk, MD, PhD, from Erasmus MC Cancer Institute in Rotterdam, Netherlands, discusses the SANO trial—a multicenter, non-inferiority, stepped wedge cluster randomized trial investigating active surveillance versus standard resection following neoadjuvant chemoradiotherapy for locally advanced esophageal cancer. Lastly, Luca Arecco, MD, from the University of Genova in Genova, Italy, comments on the prognostic implications of risk definitions from the monarchE (NCT03155997) and NATALEE (NCT03701334) trials

Stay tuned for more from the VJOncoAlert Journal Club at VJOncology.com!

Adjuvant Therapy for Hepatocellular Carcinoma

Welcome to this week's podcast by VJOncology, where we delve into the latest developments in adjuvant therapy for hepatocellular carcinoma. Join five leading experts as they discuss cutting-edge research and its impact on clinical practices.

Stephen Chan, MBBS, MRCP, The Chinese University of Hong Kong, Hong Kong, China, Laura Williams Goff, MD, MSCI, MMHC, Vanderbilt-Ingram Cancer Center, Nashville, TN, Lorenza Rimassa, MD, IRCCS Humanitas Research Hospital, Milan, Italy, Pierce Chow, MBBS, MMed (Surg), FRCS (Edin), FAMS (Gen Surg), PhD, National Cancer Centre Singapore & Duke-NUS Medical School Singapore, Singapore, and Ghassan Abou-Alfa, MD, MBA, Memorial Sloan Kettering Cancer Center, New York, NY, break down the latest research, ongoing clinical trials, and what these developments mean for clinical practice. They touch on the promising results of the IMbrave150 and IMbrave050 trial, the Phase II study of regorafenib and pembrolizumab, the KEYSTEP-004 trial and future prospects for these adjuvant therapies.

Prostate cancer awareness month: advances in liquid biopsies

In this week's VJOncology podcast, we are focusing again on Prostate Cancer Awareness Month, where we have collaborated with experts on liquid biopsies for tracking and predicting treatment outcomes in metastatic castration-resistant prostate cancer.

Join Chinmay Jani from the Sylvester Comprehensive Cancer Centre, Xin Gao from Massachusetts General Hospital Cancer Center, Christos Kyriakopoulos from the University of Wisconsin, Andrew Armstrong from the Duke Cancer Institute, and Susan Halabi from Duke University Medical Center, as they present various trial updates and their exclusive insights from this burgeoning field. 

BTOG 2025 highlights

In this weeks VJOncology podcast, we explore key update from BTOG 2025 in thoracic oncology.

Prof. Sanjay Popat discusses the evolving role of ADCs in lung cancer treatment, focusing on efficacy, toxicity management, and biomarker integration. Prof. Samreen Ahmed examines ADC resistance mechanisms, drawing insights from breast cancer therapy to refine drug development strategies. Prof. Robert Rintoul reviews a new UK Lung Cancer Coalition report on genomic testing challenges and strategic solutions for faster diagnostics. Dr Adam Januszewski highlights the complexities of implementing genomics in the UK and the need for a streamlined approach. Prof. Neal Nivani concludes by reflecting on BTOG 2025’s success and NHS England’s new service specification.

Liquid biopsy in breast cancer

In this weeks VJOncology podcast, three oncology experts delve into the transformative potential of liquid biopsy in breast cancer treatment.

First, Michail Ignatiadis (Jules Bordet Institute, Brussels, Belgium) discusses the clinical applications and challenges of utilizing liquid biopsy in metastatic breast cancer, focusing on the Phase III TREAT ctDNA trial (NCT05512364) and its implications for ER-positive, HER2-negative cases. Next, Marina Sharifi (University of Wisconsin Carbone Cancer Center, Madison, WI) introduces an innovative fragmentomic analysis of circulating tumor DNA (CT-DNA) to discern estrogen receptor status in metastatic breast cancer, potentially minimizing the need for invasive tissue biopsies. Finally, Guilherme Nader-Marta (Dana-Farber Cancer Center, Boston, MA) shares insights from the PACE trial (NCT03147287), highlighting two pivotal studies that explore biomarkers in ER-positive, HER2-negative metastatic breast cancer and underscore the prognostic value of liquid biopsy in optimizing treatment strategies.

 

For more updates on breast cancer, be sure to visit our dedicated Breast Cancer Channel.

Prostate cancer awareness month: developments in radioligand therapy

In this podcast, we will discuss recent developments in radioligand therapy for metastatic castration-resistant prostate cancer (mCRPC) treatment, as part one of our series for Prostate Cancer Awareness Month. Listen to leading experts as they share breakthroughs in mCRPC research.

 

First, Omid Yazdanpanah, MD, from the University of California, shares findings from the VISION trial, which assessed 177Lu-PSMA-617 with or without androgen receptor pathway inhibitors (ARPIs) in patients with mCRPC, as well as the potential of radioligands with ARPIs in in the ENZA-p trial. Andrei Gafita, MD, from Johns Hopkins Medicine, subsequently discusses the significance of post-therapy LuPSMA-SPECT/CT in patients with mCRPC and Umang Swami, MD, MS, from the University of Utah gives an overview of findings from the PRO-XL trial. Michael Morris, from Memorial Sloan Kettering Cancer Center, ends the podcast by addressing the challenges in using radioligand therapy for patients with metastatic castration-resistant prostate cancer.

Key updates at ASCO GU 2025: STAMPEDE, CheckMate 214, and more

Join us in this episode as we go through the latest advancements in genitourinary cancer treatment presented at ASCO GU 2025 in San Francisco. Our expert guests provide insights into ground-breaking trials and studies that are reshaping the landscape of cancer therapy.

Join Nadine Houede, Xinan Sheng, Nicholas James, and Wenxin Xu, as they discuss highly anticipated updates such as results of neoadjuvant durvalumab with chemotherapy in high-risk high-risk upper tract urothelial carcinoma (UTUC), disitamab vedotin and toripalimab in HER2-expressing bladder cancer, and updates from the STAMPEDE trial. 

Cellular therapies in solid tumors

Welcome to this week's podcast by VJOncology, where we delve into the emerging trends and challenges in the field of cellular therapies for oncology. Our expert panel includes Leonardo Ferreira (The Medical University of South Carolina, Charleston, SC), who discusses the groundbreaking potential and current obstacles of CAR T cells in treating solid tumors, emphasizing the innovative role of chimeric antigen receptor regulatory T cells.

We also hear from Sebastian Klobuch (Netherlands Cancer Institute, Amsterdam, The Netherlands) on the advancements in TIL and TCR-modified therapies. He explores potential ways to mitigate treatment toxicities and expand the applicability of these therapies beyond melanoma.

Andrew Furness (Royal Marsden Hospital, London, UK) highlights the promise of TIL therapy for melanoma, while addressing regulatory challenges. Allison Betof Warner (Stanford Cancer Center, Stanford, CA) provides insights into the evolving use of life looser in managing melanoma cases with brain metastases, alongside a specially designed pilot trial to explore treatment safety.

Mina Lobbous (Case Western Reserve University, Cleveland, OH) shares updates on gene-modified gamma-delta T cells targeting glioblastoma multiforme, focusing on phase one trial outcomes and future directions for improving patient survival rates.